**Appendix Table E50. Phenotypic test details in a single study assessing the predictive ability of VASP in patients with ischemic heart, cerebrovascular and peripheral vascular disease**

| **Author, year [ref]**  **UID**  **Country**  **Study Name** | **Test/Device name**  **Device category Device name & manufacturer\*** | **Agonist used** | **Sample Collection and Procurement**  **Anticoagulant used**  **Interval between clopidogrel doses and blood sampling (in days)**  **Interval between sampling and testing (in days):** | **Grouping of Phenotypes [Definition]** | **Rational for the grouping of phenotypes reported (Yes/No)**  **[short description]** | **Frequency of phenotypes** |
| --- | --- | --- | --- | --- | --- | --- |
| Reny, 2012{Reny, 2012 18240 /id}  22615340  France and Switzerland  ADRIE | VASP  FACS Calibur flow cytometer  Becton Dickinson, san Jose, CA, USA  VASP/P2Y12 kit (BioCytex, Marseille,France) | ADP+PGE1 (prostaglandin E1) | Blood samples collected after antiplatelet therapy intake  0.105 mol/L sodium citrate (1  vol/9 vol)  3 hrs  NR | PRI ≥50%  PRI <50% | Based on literature | ≥50%: 226  <50%: 221 |